Back To Search Results

Central Serous Chorioretinopathy

Editor: Koushik Tripathy Updated: 8/25/2023 3:04:39 AM


Central serous chorioretinopathy (CSCR) is a retinal disorder characterized by localized serous detachment of the macula with or without focal serous pigment epithelial detachment (PED). It is mostly seen in young men aged 20–45 years.[1] Albert V Graefe first described this condition as central recurrent retinitis in 1866. Bennet coined the term “central serous retinopathy,” and Gass described the pathogenesis.[2] The patient complains of distorted images, the apparent small size of objects, and blurred vision. Most of the cases resolve spontaneously in 3-6 months.[3] For non-resolving cases, treatment includes laser photocoagulation and photodynamic therapy.[4][5] AntiVEGF and mineralocorticoid receptor antagonists have also been tried.[6][7][8]


Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care


  • Yannuzzi suggested a relationship between CSCR and type A personality.[9] These persons are aggressive, competitive, and have a sense of urgency. Such behavior causes catecholamine release, which increases choroidal permeability.[10] 
  • Psychological stress and depression also predispose to CSCR.[11]
  • A definite association exists between CSCR and exogenous corticosteroid use.[12][13] It is generally associated with systemic intake, either oral or intravenous.[13][14] But studies have reported CSCR after nasal spray, topical skin creams, intra-articular, epidural, or periocular use.[15]
  • CSCR has also been reported following kidney, heart, and bone marrow transplantations.[16][17] 
  • Increased endogenous cortisol production, such as Cushing disease and pregnancy, increases the risk of CSCR.[18] Steroid-effect might be an idiosyncratic response that affects vascular autoregulation.
  • Drugs other than corticosteroids that have been associated with CSCR are
    • oral MEK inhibitors
    • phosphodiesterase inhibitors
    • pseudoephedrine
    • oxymetazoline[17][19][20][21]
  • Association between H. pylori infection, peptic ulcer disease and CSCR has been reported in some studies.[22][23]
  • It is associated with stress and sleep disturbances. Treatment of the underlying cause resolves CSCR.[24][25][26]
  • Familial association of CSCR has been reported.[27][28][29]
  • Single nucleotide polymorphisms in complement factor H and cadherin 4 is thought to be associated.[15]
  • CSCR associated pachychoroid can be inherited as a dominant trait.[30][31]
  • Other systemic associations of CSCR include
    • Sleep apnea syndrome
    • Systemic hypertension
    • Psychopharmacologic medications
    • Systemic lupus erythematosus[32]
    • Gastroesophageal reflux disease[24]


CSCR is the fourth most common retinal disorder threatening the vision.[33] Men are commonly affected. The male-female ratio was found to be 6:1 in a population-based study.[34] The mean age group is 39-51 years.[34][35] When females are affected, the age is usually higher than males. It is generally unilateral. However, bilateral involvement may be in up to 40% of cases.[36] However, the majority of cases have pigment epithelial detachment (PED) in the fellow eye also. Bilateral changes in the choroid are usually noted on optical coherence tomography (OCT)[37] and indocyanine green angiography (ICGA).[37] Kitzmann et al. found the incidence of CSCR to be 9.9 cases per 100,000 population.[34]


The pathophysiology of CSCR is multifactorial, which causes retinal pigment epithelial (RPE) disturbances and circulatory changes in the choroid.[38] There is choroidal inflammation, which causes stasis and ischemia.[22][38][39] The choroidal vessels become hyperpermeable, and the choroid becomes thickened. This leads to increased tissue pressure, which disturbs the anatomic integrity of RPE and causes PED. The micro-defects in the RPE hamper its barrier functions. The choroidal fluid crosses the RPE and cause neurosensory detachment. It gets collected in the subretinal space. Another hypothesis is the loss of polarity of RPE.[40] 

Normally, the RPE keeps the retina in a dehydrated state by pumping out fluid from the subretinal space to the choroid. With the loss of polarity, the pumping reverses and fluid is directed towards the subretinal space. The non-perfusion in the choriocapillaris may lead to the widening of venous channels and increased hydrostatic pressure.[22][39] The mineralocorticoid receptor pathway has also been implicated.

Experiments have shown that intravitreal injection of aldosterone causes dilatation of choroidal veins and congestion, which leads to the accumulation of fluid in the subretinal space.[41] The widespread choroidal hyperpermeability can be seen with indocyanine green angiography (ICGA).[38] Enhanced depth imaging optical coherence tomography (EDI-OCT) has demonstrated increased choroidal thickness and congestion.[42] On ICGA, areas of choroidal staining adjacent to the site of RPE leakage have been shown.[43][44]

History and Physical

The patient complains of unilateral blurred vision, micropsia, metamorphopsia, relative scotoma, and color vision disturbances. There is temporary hyperopia. Vision ranges from 6/9-6/60, though in most cases, it is better than 6/12. On examination, there is a well defined circular or oval area of neurosensory detachment over the posterior pole. Occasionally, a yellowish feathered-edge subretinal material (presumably fibrin) and PED may also be seen.[45] 

The acute episode generally resolves within 3 to 6 months. If fluid persists beyond this period, it is called “chronic CSCR.” It is generally seen in older patients or those receiving long term corticosteroids.[11][46] Atypical CSCR presents as inferior bullous retinal detachment. Such cases may be associated with multifocal PED, multifocal neurosensory retinal detachments, and multiple leaks on fundus fluorescein angiogram (FFA).[47]


Ancillary tests

OCT (optical coherence tomography)

This is the first line of investigation. The presence of subretinal fluid (SRF) is characteristic of CSCR. The resolution of SRF can be documented on serial OCT. Sometimes band-like fibrin deposits can be seen in the subretinal space.[48] Outer retinal dipping may be noted, which may touch the RPE or a PED.[49] The area of retinal dipping/sagging may denote the location of the leak.[49] In chronic CSCR intraretinal cystic changes, hyperreflective dots and elongated photoreceptor outer segments may be present. CSCR is currently considered as part of the pachychoroid spectrum. Thicker choroid has been demonstrated on EDI OCT in eyes with CSCR and fellow eyes. Dilatation of outer choroidal vessels and thinning of choriocapillaris is present.[14][18][50][51] PED is commonly seen. It is contiguous to areas of choroidal hyperpermeability, as evident on ICGA. Sometimes a double layer sign can be seen in chronic CSCR.[52] However, this sign is typically seen in idiopathic polypoidal choroidopathy (IPCV)IPCV and CSCR constitute the pachychoroid spectrum and ICGA helps in differentiating the two. Tiny white dots may be seen in CSCR on ophthalmoscopy, which appear as hyper-reflective dots in the outer retina on OCT.

Fundus autofluorescence (FAF)

In acute CSCR, focal areas of hypo-autofluorescence are seen that may correspond to the leak on FFA. In chronic CSCR, hyper-autofluorescent tracks are present due to the accumulation of photoreceptor pigments.

Fundus fluorescein angiography (FFA)

Three types of fluorescein leakage patterns are seen in CSCR- inkblot, smokestack, and diffuse. In the inkblot pattern, pinpoint leakage occurs in the early phase, which then concentrically enlarges in the late phase. In smokestack pattern, the leakage starts as a pinpoint and gradually expands to form an umbrella-like (or tree-like) appearance. Inkblot pattern is more common. In the diffuse leak, there are multiple small/inconspicuous leaks in a localized area, which cause an increase in the size and intensity of the area of hyper-fluorescence. In chronic CSCR, patchy areas of hyper-fluorescence are seen corresponding to areas of RPE atrophy. Serous PED shows early hyper-fluorescence with a progressive increase in the intensity, but size remains the same.

Indocyanine green angiography (ICGA)

ICGA is helpful in imaging the choroidal vasculature. It shows hypocyanescence in the early phase denoting choriocapillaris nonperfusion and delayed filling. In mid-phase, hypercyanescence is seen, indicating choroidal vessel hyperpermeability. This hypercyanescence slowly fades in the late phase.[21][22][29] These changes are bilateral. ICGA also helps in the detection of a choroidal neovascularized membrane (CNVM) in chronic CSCR, which may occur in up to 23% of cases.[22][53]

OCT angiography (OCTA)

It is useful in detecting CNVM in chronic CSCR by a non-invasive method. It shows dilated choriocapillaris in most eyes with CSCR.[34] Abnormal choroidal flow patterns suggestive of choroidal ischemia with surrounding hyperperfusion are seen in acute and chronic CSCR.[35] Dilated choroidal vessels are detected as high flow, well-delineated channels.[46] The SRF is seen as dark areas at the level of choriocapillaris. The PED is detected as dark spots. OCTA is being increasingly used to identity CNVM in CSCR and may detect CNVM in up to 20% cases of chronic CSCR.[53]

Treatment / Management

The majority of cases of CSCR resolve spontaneously, so observation is done for 3-6 months.[22] In some cases, CSCR persists beyond 6 months or recurs. Chronic CSCR leads to macular degeneration, foveal atrophy, and RPE changes. In these cases, active treatment should be initiated.[54] If the patient is on steroids for a medical condition, then they should be discontinued and alternative therapy should be taken if possible. As CSCR of long duration may cause an irreversible visual decline, some clinicians may plan to treat early. Usually, for the first episode of CSCR, most clinicians observe (with reduction of stress/stoppage of steroids or other predisposing factors) for the initial few months as more than 80% cases resolve spontaneously.(B3)

Indications for early intervention include

  • Visual demand of profession (pilot) or the patient for early recovery
  • Recurrent disease
  • Severe decline of vision in the other eye due to chronic CSCR

Laser photocoagulation:

The RPE leakage sites, as seen on angiography, can be treated with laser photocoagulation. Such therapy seals the leakage point and hastens the resolution of subretinal fluid.[55] The thermal laser is indicated for extrafoveal leakage points. A green-wavelength laser produces a light gray scar over the focal RPE leak. Spot size is 100 micrometers, duration ≤0.1-second, and power ranging from 70-120 milliwatts is used. It should be applied judiciously as it may cause scotoma and laser-induced choroidal neovascularization.[55][56][57] The laser does not reduce the chances of recurrence. To overcome these problems, a micropulse laser can be used.[58][59][60][61] It is a diode or yellow laser which emits micropulses and delivers subthreshold laser energy without a visible burn. This stimulates the surrounding RPE cells and seals the defect. Some studies have reported faster visual recovery with this therapy.[62] (A1)

Photodynamic therapy (PDT)

CSCR with a subfoveal leak, juxtafoveal leak, multiple leaks, and chronic cases with diffuse decompensation of RPE are better managed with PDT. PDT causes vascular remodeling of the choroid and choroidal hypoperfusion.[63][64] A drug called verteporfin is injected intravenously, which then reaches the eye. The verteporfin is activated by a laser on the source of leakage. This seals the RPE defect. It may also prevent future recurrences in some eyes. It appears to be a more effective treatment with a lower complication rate. Using EDI-OCT, the choroid can be monitored for thinning after treatment with PDT.[4] Low fluence PDT has improved efficacy and safety profile in chronic CSCR cases.[65][66](A1)

Anti-vascular growth factor (VEGF):

Anti VEGF therapy has been proposed to reduce choroidal hyperpermeability. They upregulate the tight junctions between endothelial cells and the reduction of vascular fenestrations.[67][68][69] Various studies have reported the effect of bevacizumab, ranibizumab, and aflibercept on CSCR.[70][71][72] Results remain inconclusive, and long term benefits warrant more studies. There is no level 1 or level 2 evidence for the use of anti-VEGF agents in CSCR though they have a definite role in CSCR related choroidal neovascularization or IPCV, which is a close differential diagnosis.(B2)


Patients with CSCR commonly have endogenous hypercortisolism, thus drugs targeting cortisol pathways might be effective.[73] Ketoconazole is an antifungal agent which has anti glucocorticoid effects. It blocks the conversion of cholesterol to androgenic glucocorticoid end-products. Few studies have investigated ketoconazole as a treatment for CSCR without any significant benefit.[74] (B3)

Mifepristone (RU-486) is an abortifacient agent. Its mechanism of action is mediated through its glucocorticoid and progesterone receptor antagonistic effects. It has been used in chronic CSCR patients with varied responses.[75](B3)

Finasteride is a weak anti-androgen that works through inhibiting type II 5 alpha-reductase that is necessary for converting testosterone to dihydrotestosterone (DHT), a potent androgen. It has been investigated in CSCR, but more trials are needed to evaluate the effect.[76] (B3)

Eplerenone, a selective aldosterone-receptor antagonist and potassium-sparing diuretic, was originally approved in 2002 by the FDA for the treatment of hypertension. The medication is generally well-tolerated, but drug interactions must be ruled out prior to initiation, and serum potassium and blood pressure must be monitored during treatment. Studies have shown it to improve visual acuity and decrease central macular thickness in a small series of patients with chronic CSCR.[77][78][79][80] Currently, its use in CSCR remains investigational and is not considered standard of care. Further studies are warranted to further clarify the role of aldosterone receptor antagonists in CSCR. A randomized control trial could not find the superiority of eplerenone to placebo in improving vision in chronic CSCR, and the authors recommended against its use for this indication.[81](A1)

Rifampicin is an anti-tuberculous medication that facilitates the catabolism of endogenous steroids. It increases the cytochrome P-450 content in the liver, thus affecting the metabolism and bioavailability of endogenous corticosteroids, consequently aiding in the resolution of CSCR and improving its symptomatology.[82][83][84] However, care is to be taken as hepatotoxicity can develop as a side effect while being treated for CSCR.(B3)

Adrenergic blockers

As CSCR is closely associated with type A personality, which is characterized by high adrenergic activity, it was proposed that blocking adrenergic receptors might have a positive effect on CSCR.[84] It has been shown that CSCR patients who were diagnosed with hypertension and were started on metoprolol, a beta-blocker, had improved clinically.[85][23] [85]However, further assessment of the actual role of adrenergic blockers needs to be tested.(B3)

Anti-Helicobacter pylori treatment

The therapy of Helicobacter pylori-related peptic ulcer disease has shown variable results in CSCR.[23] However, peptic ulcer disease may be looked for in patients with chronic CSCR, and its management adds to the available therapy for chronic CSCR.

Differential Diagnosis

Other diseases of choroid and retina can closely mimic CSCR. They are ARMD (age-related macular degeneration), IPCV, and optic disc pit associated maculopathy. ARMD is seen in patients above 50 years. Chronic CSCR can develop secondary CNVM on follow up or after laser photocoagulation.

OCT angiography is helpful in delineating the neovascular complex of ARMD. EDI OCT shows thicker choroid in CSCR and thin to normal choroid in ARMD. IPCV produces serous macular detachment and RPE changes similar to CSCR. The polyp and branching vascular network are characteristic findings on ICGA. OCT typically shows serosanguinous or notched PED.

Optic disc pit causes serous macular detachment at the macula. On careful slit-lamp biomicroscopy, focal excavation can be seen on the temporal part of the optic disc. Retinal schisis is commonly observed in optic disc pit, while these changes are infrequently seen only in chronic CSCR. The sub-internal limiting membrane cavity after the resolution of sub-internal limiting membrane hemorrhage (including after Valsalva retinopathy) may simulate CSCR on cursory examination.[86]


Most of the cases resolve spontaneously by 3-6 months. Some cases persist beyond 6 months. Such cases of chronic CSCR need treatment. Recurrence may be noted in up to 50% of untreated cases.[87]


Chronic CSCR cases, if not treated, can have complications. Chronic CSCR with PED can develop RPE rip with secondary exudative retinal detachment. Such patients complain of sudden diminution of vision. Other complications can be CNVM and macular degeneration. Diffuse retinal pigment epitheliopathy in CSCR may be the cause of the irreversible visual decline.

Deterrence and Patient Education

The patient should be counseled properly regarding the prognosis of CSCR. Acute idiopathic cases require observation and avoidance of predisposing factors.

Enhancing Healthcare Team Outcomes

Any patient presenting with CSCR should receive treatment by an ophthalmologist and an interprofessional team evaluation by primary clinicians and endocrinologists. Interprofessional communication can lead to better patient management. The patient will most often present to the primary clinician, and these professionals should be aware of the condition as it is treatable. Prompt referral to an ophthalmologist is necessary.

These patients can then be followed by their primary clinicians and should ensure compliance with treatment. Pharmacists can ensure correct dosing on the medication management aspect of the condition. Nursing will be the first in the department to come in contact with patients on followup and can assess treatment progress as well as evaluate compliance with both medication and lifestyle measures, and report any issues to the primary care clinician. This collaborative, interprofessional approach to care can ensure optimal patient outcomes.



Liu B, Deng T, Zhang J. RISK FACTORS FOR CENTRAL SEROUS CHORIORETINOPATHY: A Systematic Review and Meta-Analysis. Retina (Philadelphia, Pa.). 2016 Jan:36(1):9-19. doi: 10.1097/IAE.0000000000000837. Epub     [PubMed PMID: 26710181]

Level 1 (high-level) evidence


Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. American journal of ophthalmology. 1967 Mar:63(3):Suppl:1-139     [PubMed PMID: 6019308]


Baran NV, Gürlü VP, Esgin H. Long-term macular function in eyes with central serous chorioretinopathy. Clinical & experimental ophthalmology. 2005 Aug:33(4):369-72     [PubMed PMID: 16033348]


Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010 Sep:117(9):1792-9. doi: 10.1016/j.ophtha.2010.01.023. Epub 2010 May 15     [PubMed PMID: 20472289]

Level 2 (mid-level) evidence


Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. American journal of ophthalmology. 2004 Jun:137(6):1073-80     [PubMed PMID: 15183792]

Level 2 (mid-level) evidence


Arevalo JF, Espinoza JV. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2011 Aug:249(8):1159-66. doi: 10.1007/s00417-011-1651-7. Epub 2011 Mar 30     [PubMed PMID: 21448811]

Level 3 (low-level) evidence


Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Current eye research. 2010 Feb:35(2):91-8. doi: 10.3109/02713680903428306. Epub     [PubMed PMID: 20136418]

Level 1 (high-level) evidence


Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2011 Jul:249(7):969-74. doi: 10.1007/s00417-010-1581-9. Epub 2010 Dec 8     [PubMed PMID: 21140161]


Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Transactions of the American Ophthalmological Society. 1986:84():799-845     [PubMed PMID: 3590481]


Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina (Philadelphia, Pa.). 2003 Feb:23(1):1-7; quiz 137-8     [PubMed PMID: 12652224]


Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, Freund B, Guyer DR, Slakter JS, Sorenson JA. Systemic findings associated with central serous chorioretinopathy. American journal of ophthalmology. 1999 Jul:128(1):63-8     [PubMed PMID: 10482095]

Level 2 (mid-level) evidence


Carvalho-Recchia CA, Yannuzzi LA, Negrão S, Spaide RF, Freund KB, Rodriguez-Coleman H, Lenharo M, Iida T. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002 Oct:109(10):1834-7     [PubMed PMID: 12359603]

Level 2 (mid-level) evidence


Karadimas P, Kapetanios A, Bouzas EA. Central serous chorioretinopathy after local application of glucocorticoids for skin disorders. Archives of ophthalmology (Chicago, Ill. : 1960). 2004 May:122(5):784-6     [PubMed PMID: 15136332]

Level 3 (low-level) evidence


Tsai DC, Chen SJ, Huang CC, Chou P, Chung CM, Chan WL, Huang PH, Lin SJ, Chen JW, Chen TJ, Leu HB. Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: a population-based study in Taiwan. Retina (Philadelphia, Pa.). 2014 Sep:34(9):1867-74. doi: 10.1097/IAE.0000000000000159. Epub     [PubMed PMID: 24743638]

Level 2 (mid-level) evidence


Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Progress in retinal and eye research. 2015 Sep:48():82-118. doi: 10.1016/j.preteyeres.2015.05.003. Epub 2015 May 27     [PubMed PMID: 26026923]


Ulbig MR, Riordan-Eva P, Holz FG, Rees HC, Hamilton PA. Membranoproliferative glomerulonephritis type II associated with central serous retinopathy. American journal of ophthalmology. 1993 Oct 15:116(4):410-3     [PubMed PMID: 8213970]

Level 3 (low-level) evidence


Michael JC, Pak J, Pulido J, de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. American journal of ophthalmology. 2003 Jul:136(1):182-5     [PubMed PMID: 12834690]

Level 3 (low-level) evidence


Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S, Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004 Feb:111(2):244-9     [PubMed PMID: 15019370]

Level 2 (mid-level) evidence


McCannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, Wainberg ZA, McCannel CA. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA ophthalmology. 2014 Aug:132(8):1005-9. doi: 10.1001/jamaophthalmol.2014.976. Epub     [PubMed PMID: 24852144]

Level 3 (low-level) evidence


Aliferis K,Petropoulos IK,Farpour B,Matter MA,Safran AB, Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2012;     [PubMed PMID: 22156704]

Level 3 (low-level) evidence


Pierce KK, Lane RG. Central serous chorioretinopathy associated with the use of ephedra. Retinal cases & brief reports. 2009 Fall:3(4):376-8. doi: 10.1097/ICB.0b013e31818ad3ce. Epub     [PubMed PMID: 25389852]

Level 3 (low-level) evidence


Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. American journal of ophthalmology. 2010 Mar:149(3):361-363. doi: 10.1016/j.ajo.2009.11.017. Epub     [PubMed PMID: 20172062]

Level 3 (low-level) evidence


Tripathy K. Is Helicobacter pylori the culprit behind central serous chorioretinopathy? Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2016 Oct:254(10):2069-2070     [PubMed PMID: 27364118]


Mansuetta CC, Mason JO 3rd, Swanner J, Feist RM, White MF Jr, Thomley ML, McGwin G Jr, Emond TL. An association between central serous chorioretinopathy and gastroesophageal reflux disease. American journal of ophthalmology. 2004 Jun:137(6):1096-100     [PubMed PMID: 15183795]

Level 2 (mid-level) evidence


Cotticelli L, Borrelli M, D'Alessio AC, Menzione M, Villani A, Piccolo G, Montella F, Iovene MR, Romano M. Central serous chorioretinopathy and Helicobacter pylori. European journal of ophthalmology. 2006 Mar-Apr:16(2):274-8     [PubMed PMID: 16703546]

Level 2 (mid-level) evidence


Misiuk-Hojło M, Michałowska M, Turno-Krecicka A. Helicobacter pylori--a risk factor for the developement of the central serous chorioretinopathy. Klinika oczna. 2009:111(1-3):30-2     [PubMed PMID: 19517842]


Lin E, Arrigg PG, Kim RY. Familial central serous choroidopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2000 Nov:238(11):930-1     [PubMed PMID: 11148819]

Level 3 (low-level) evidence


Oosterhuis JA. Familial central serous retinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1996 May:234(5):337-41     [PubMed PMID: 8740256]


Park DW, Schatz H, Gaffney MM, McDonald HR, Johnson RN, Schaeffer D. Central serous chorioretinopathy in two families. European journal of ophthalmology. 1998 Jan-Mar:8(1):42-7     [PubMed PMID: 9590595]

Level 3 (low-level) evidence


Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F. PACHYCHOROID: an inherited condition? Retina (Philadelphia, Pa.). 2015 Jan:35(1):10-6. doi: 10.1097/IAE.0000000000000287. Epub     [PubMed PMID: 25046398]

Level 2 (mid-level) evidence


Gass JD. Central serous chorioretinopathy and white subretinal exudation during pregnancy. Archives of ophthalmology (Chicago, Ill. : 1960). 1991 May:109(5):677-81     [PubMed PMID: 2025170]


Cunningham ET Jr, Alfred PR, Irvine AR. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology. 1996 Dec:103(12):2081-90     [PubMed PMID: 9003342]

Level 3 (low-level) evidence


Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta ophthalmologica. 2008 Mar:86(2):126-45     [PubMed PMID: 17662099]


Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008 Jan:115(1):169-73. doi: 10.1016/j.ophtha.2007.02.032. Epub     [PubMed PMID: 18166410]

Level 2 (mid-level) evidence


Tsai DC, Chen SJ, Huang CC, Chou P, Chung CM, Huang PH, Lin SJ, Chen JW, Chen TJ, Leu HB, Chan WL. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PloS one. 2013:8(6):e66858. doi: 10.1371/journal.pone.0066858. Epub 2013 Jun 24     [PubMed PMID: 23826160]

Level 2 (mid-level) evidence


Gäckle HC, Lang GE, Freissler KA, Lang GK. [Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 1998 Aug:95(8):529-33     [PubMed PMID: 9782727]

Level 2 (mid-level) evidence


Kim YT, Kang SW, Bai KH. Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy. Eye (London, England). 2011 Dec:25(12):1635-40. doi: 10.1038/eye.2011.258. Epub 2011 Oct 21     [PubMed PMID: 22020172]

Level 2 (mid-level) evidence


Prünte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. American journal of ophthalmology. 1996 Jan:121(1):26-34     [PubMed PMID: 8554078]

Level 3 (low-level) evidence


Okushiba U, Takeda M. [Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography]. Nippon Ganka Gakkai zasshi. 1997 Jan:101(1):74-82     [PubMed PMID: 9028111]


Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1986:224(4):321-4     [PubMed PMID: 3710187]


Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. The Journal of clinical investigation. 2012 Jul:122(7):2672-9. doi: 10.1172/JCI61427. Epub 2012 Jun 11     [PubMed PMID: 22684104]

Level 3 (low-level) evidence


Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, Matsumoto A, Yoshimura N. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology. 2012 Aug:119(8):1666-78. doi: 10.1016/j.ophtha.2012.02.021. Epub 2012 Apr 21     [PubMed PMID: 22521082]

Level 2 (mid-level) evidence


Uyama M, Matsunaga H, Matsubara T, Fukushima I, Takahashi K, Nishimura T. Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Retina (Philadelphia, Pa.). 1999:19(1):12-21     [PubMed PMID: 10048368]

Level 3 (low-level) evidence


Yannuzzi LA,Slakter JS,Gross NE,Spaide RF,Costa D,Huang SJ,Klancnik JM Jr,Aizman A, Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina (Philadelphia, Pa.). 2003 Jun;     [PubMed PMID: 12824827]

Level 3 (low-level) evidence


Wang M, Sander B, la Cour M, Larsen M. Clinical characteristics of subretinal deposits in central serous chorioretinopathy. Acta ophthalmologica Scandinavica. 2005 Dec:83(6):691-6     [PubMed PMID: 16396646]

Level 2 (mid-level) evidence


Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996 Dec:103(12):2070-9; discussion 2079-80     [PubMed PMID: 9003341]

Level 2 (mid-level) evidence


Balaratnasingam C, Freund KB, Tan AM, Mrejen S, Hunyor AP, Keegan DJ, Dansingani KK, Dayani PN, Barbazetto IA, Sarraf D, Jampol LM, Yannuzzi LA. Bullous Variant of Central Serous Chorioretinopathy: Expansion of Phenotypic Features Using Multimethod Imaging. Ophthalmology. 2016 Jul:123(7):1541-52. doi: 10.1016/j.ophtha.2016.03.017. Epub 2016 Apr 12     [PubMed PMID: 27084564]


Imasawa M, Ohshiro T, Gotoh T, Imai M, Iijima H. Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta ophthalmologica Scandinavica. 2005 Feb:83(1):132-3     [PubMed PMID: 15715582]

Level 3 (low-level) evidence


Kim HC, Cho WB, Chung H. Morphologic changes in acute central serous chorioretinopathy using spectral domain optical coherence tomography. Korean journal of ophthalmology : KJO. 2012 Oct:26(5):347-54. doi: 10.3341/kjo.2012.26.5.347. Epub 2012 Sep 24     [PubMed PMID: 23060721]

Level 2 (mid-level) evidence


Haimovici R, Gragoudas ES, Duker JS, Sjaarda RN, Eliott D. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology. 1997 Oct:104(10):1653-60     [PubMed PMID: 9331207]

Level 3 (low-level) evidence


Kleinberger AJ, Patel C, Lieberman RM, Malkin BD. Bilateral central serous chorioretinopathy caused by intranasal corticosteroids: a case report and review of the literature. The Laryngoscope. 2011 Sep:121(9):2034-7. doi: 10.1002/lary.21967. Epub 2011 Aug 16     [PubMed PMID: 22024860]

Level 3 (low-level) evidence


Yang L, Jonas JB, Wei W. Optical coherence tomography-assisted enhanced depth imaging of central serous chorioretinopathy. Investigative ophthalmology & visual science. 2013 Jul 12:54(7):4659-65. doi: 10.1167/iovs.12-10991. Epub 2013 Jul 12     [PubMed PMID: 23737472]


Stattin M, Ahmed D, Forster J, Glittenberg C, Herrmann M, Krebs I, Ansari-Shahrezaei S. Detection of secondary choroidal neovascularization in chronic central serous chorioretinopathy by swept source-optical coherence tomography angiography. Acta ophthalmologica. 2019 Feb:97(1):e135-e136. doi: 10.1111/aos.13855. Epub 2018 Oct 3     [PubMed PMID: 30284407]


Wang MS, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. American journal of ophthalmology. 2002 Jun:133(6):787-93     [PubMed PMID: 12036670]


Lim JW, Kang SW, Kim YT, Chung SE, Lee SW. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. The British journal of ophthalmology. 2011 Apr:95(4):514-7. doi: 10.1136/bjo.2010.182121. Epub 2010 Jul 19     [PubMed PMID: 20644214]

Level 2 (mid-level) evidence


Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. American journal of ophthalmology. 1983 Apr:95(4):457-66     [PubMed PMID: 6682293]

Level 1 (high-level) evidence


Gärtner J. Long-term follow-up of an ophthalmologist's central serous retinopathy, photocoagulated by sungazing. Documenta ophthalmologica. Advances in ophthalmology. 1987 May:66(1):19-33     [PubMed PMID: 3428072]

Level 3 (low-level) evidence


Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: evolution and clinical applications. Survey of ophthalmology. 2010 Nov-Dec:55(6):516-30. doi: 10.1016/j.survophthal.2010.02.005. Epub 2010 Sep 20     [PubMed PMID: 20850854]

Level 3 (low-level) evidence


Gupta B, Elagouz M, McHugh D, Chong V, Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clinical & experimental ophthalmology. 2009 Nov:37(8):801-5. doi: 10.1111/j.1442-9071.2009.02157.x. Epub     [PubMed PMID: 19878226]

Level 3 (low-level) evidence


Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008 Dec:115(12):2229-34. doi: 10.1016/j.ophtha.2008.08.026. Epub     [PubMed PMID: 19041477]


Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. European journal of ophthalmology. 2008 Nov-Dec:18(6):934-40     [PubMed PMID: 18988165]

Level 3 (low-level) evidence


Verma L, Sinha R, Venkatesh P, Tewari HK. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]. BMC ophthalmology. 2004 Oct 29:4():15     [PubMed PMID: 15516262]

Level 3 (low-level) evidence


Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008 Oct:115(10):1756-65. doi: 10.1016/j.ophtha.2008.04.014. Epub 2008 Jun 5     [PubMed PMID: 18538401]

Level 1 (high-level) evidence


Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Archives of ophthalmology (Chicago, Ill. : 1960). 2002 Jun:120(6):835-44     [PubMed PMID: 12049594]


Alcubierre R, Arias L, Lorenzo D, Pujol O, Rubio M. [Low-fluence photodynamic therapy in chronic central serous chorioretinopathy]. Archivos de la Sociedad Espanola de Oftalmologia. 2012 Jan:87(1):3-8. doi: 10.1016/j.oftal.2011.06.012. Epub 2011 Sep 14     [PubMed PMID: 22248651]

Level 2 (mid-level) evidence


Butler AL, Fung AT, Merkur AB, Albiani DA, Forooghian F. Very minimal fluence photodynamic therapy for chronic central serous chorioretinopathy. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2012 Feb:47(1):42-4. doi: 10.1016/j.jcjo.2011.12.020. Epub     [PubMed PMID: 22333850]

Level 3 (low-level) evidence


Witkin AJ, Brown GC. Update on nonsurgical therapy for diabetic macular edema. Current opinion in ophthalmology. 2011 May:22(3):185-9. doi: 10.1097/ICU.0b013e3283459724. Epub     [PubMed PMID: 21427573]

Level 3 (low-level) evidence


Chiang A, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Current opinion in ophthalmology. 2011 May:22(3):199-204. doi: 10.1097/ICU.0b013e32834597d9. Epub     [PubMed PMID: 21427571]

Level 3 (low-level) evidence


London NJ, Brown G. Update and review of central retinal vein occlusion. Current opinion in ophthalmology. 2011 May:22(3):159-65. doi: 10.1097/ICU.0b013e3283459737. Epub     [PubMed PMID: 21460724]

Level 3 (low-level) evidence


Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. American journal of ophthalmology. 2007 Jun:143(6):977-983     [PubMed PMID: 17459318]


Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. European journal of ophthalmology. 2010 Sep-Oct:20(5):955-8     [PubMed PMID: 20306440]

Level 2 (mid-level) evidence


Broadhead GK, Chang A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2015 Jun:253(6):979-81. doi: 10.1007/s00417-014-2891-0. Epub 2014 Dec 31     [PubMed PMID: 25547617]

Level 3 (low-level) evidence


Jampol LM, Weinreb R, Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies. Ophthalmology. 2002 Oct:109(10):1765-6     [PubMed PMID: 12359592]


Golshahi A, Klingmüller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta ophthalmologica. 2010 Aug:88(5):576-81. doi: 10.1111/j.1755-3768.2008.01467.x. Epub 2009 May 12     [PubMed PMID: 19456313]

Level 3 (low-level) evidence


Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina (Philadelphia, Pa.). 2011 Oct:31(9):1928-36. doi: 10.1097/IAE.0b013e31821c3ef6. Epub     [PubMed PMID: 21878843]

Level 3 (low-level) evidence


Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina (Philadelphia, Pa.). 2011 Apr:31(4):766-71. doi: 10.1097/IAE.0b013e3181f04a35. Epub     [PubMed PMID: 21273946]

Level 3 (low-level) evidence


Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina (Philadelphia, Pa.). 2013 Nov-Dec:33(10):2096-102. doi: 10.1097/IAE.0b013e318297a07a. Epub     [PubMed PMID: 23719402]

Level 3 (low-level) evidence


Maier M, Stumpfe S, Feucht N, Strobl P, Rath V, Lohmann CP. [Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2014 Feb:111(2):173-80. doi: 10.1007/s00347-013-3001-0. Epub     [PubMed PMID: 24510173]

Level 3 (low-level) evidence


Breukink MB, den Hollander AI, Keunen JE, Boon CJ, Hoyng CB. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta ophthalmologica. 2014 Sep:92(6):e488-90. doi: 10.1111/aos.12392. Epub 2014 Apr 2     [PubMed PMID: 24698599]

Level 3 (low-level) evidence


Gruszka A. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. European review for medical and pharmacological sciences. 2013 May:17(10):1369-73     [PubMed PMID: 23740451]

Level 3 (low-level) evidence


Lotery A, Sivaprasad S, O'Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC, VICI trial investigators. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2020 Jan 25:395(10220):294-303. doi: 10.1016/S0140-6736(19)32981-2. Epub     [PubMed PMID: 31982075]

Level 1 (high-level) evidence


Steinle NC, Gupta N, Yuan A, Singh RP. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. The British journal of ophthalmology. 2012 Jan:96(1):10-3. doi: 10.1136/bjophthalmol-2011-300183. Epub 2011 Nov 3     [PubMed PMID: 22053102]

Level 3 (low-level) evidence


Ravage ZB, Packo KH, Creticos CM, Merrill PT. Chronic central serous chorioretinopathy responsive to rifampin. Retinal cases & brief reports. 2012 Winter:6(1):129-32. doi: 10.1097/ICB.0b013e3182235561. Epub     [PubMed PMID: 25390732]

Level 3 (low-level) evidence


Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2006 Apr:22(2):145-9     [PubMed PMID: 16722801]

Level 3 (low-level) evidence


Avci R, Deutman AF. [Treatment of central serous choroidopathy with the beta receptor blocker metoprolol (preliminary results)]. Klinische Monatsblatter fur Augenheilkunde. 1993 Mar:202(3):199-205     [PubMed PMID: 8510413]

Level 3 (low-level) evidence


Tripathy K, Chawla R, Vekaria L, Sharma YR. Sub-internal Limiting Membrane Cavity Following Valsalva Retinopathy Resembling Central Serous Chorioretinopathy. Journal of ophthalmic & vision research. 2018 Jan-Mar:13(1):83-84. doi: 10.4103/jovr.jovr_192_16. Epub     [PubMed PMID: 29403598]


Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. The British journal of ophthalmology. 1984 Nov:68(11):815-20     [PubMed PMID: 6541945]